ARDX Stock Risk & Deep Value Analysis
Ardelyx Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on ARDX
We analyzed Ardelyx Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARDX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈ARDX Performance Overview3yr weekly
Unlock ARDX Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
ARDX Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium-High
Market Risk
Medium
About Ardelyx Inc (ARDX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$1.39B
ARDX Deep Value Analysis
Compare ARDX to Similar Stocks
See how Ardelyx Inc stacks up against related companies in our head-to-head analysis.
ARDX Red Flags & Warning Signs
Premium- ⚠
Slower-than-expected Xphozah sales growth or adoption rates
- ⚠
Unexpected clinical trial failures for pipeline candidates or label expansion
- ⚠
Increased competition from new or existing phosphate binders
- ⚠
Significant dilution from future capital raises
Unlock ARDX Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
ARDX Financial Health Metrics
Market Cap
$1.39B
ARDX Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
Xphozah's patented novel mechanism provides a distinct clinical advantage over existing phosphate binders, fostering physician adoption and patient loyalty. This differentiation is supported by clinical evidence, making it difficult for competitors to replicate in the near term.
ARDX Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
ARDX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated mid-May 2026), focusing on Xphozah sales
- •Updates on Xphozah market penetration and patient adherence rates
- •Potential analyst upgrades and increased price targets
Medium-Term (6-18 months)
- •Full Year 2026 Xphozah revenue guidance and profitability roadmap
- •Progress on international expansion (e.g., potential EU regulatory filings/approvals)
- •Clinical data updates for potential label expansion of tenapanor in other indications
Long-Term (18+ months)
- •Xphozah becoming a standard of care for refractory hyperphosphatemia, achieving blockbuster status
- •Sustained profitability and positive free cash flow generation
- •Pipeline expansion or strategic M&A activities
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
ARDX Bull Case: What Could Go Right
- ✓
Acceleration in Xphozah net product sales and patient growth rates
- ✓
Clear path and timeline to achieving operational profitability
- ✓
Positive updates on label expansion or international market entry
Bull Case Analysis
See what could go right with Premium
Never miss a move on ARDX
Create a free account to set price alerts and get notified on Telegram when ARDX hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Ardelyx Inc (ARDX)?
As of March 20, 2026, Ardelyx Inc has a DVR Score of 8.8 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Ardelyx Inc?
Ardelyx Inc's market capitalization is approximately $1.4B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Ardelyx Inc use?
ARDX is the ticker symbol for Ardelyx Inc. The company trades on the NGM.
What is the risk level for ARDX stock?
Our analysis rates Ardelyx Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the ARDX DVR analysis updated?
Our AI-powered analysis of Ardelyx Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 20, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.